Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Sci. Signal., 21 April 2009 PERSPECTIVESThe Pharmacology of mTOR InhibitionDavid A. Guertin1 and David M. Sabatini1,2,3*
1 Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02141, USA. Abstract: A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)–based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic. * Corresponding author. Telephone, 617-258-6407; e-mail, sabatini{at}wi.mit.edu
Citation: D. A. Guertin, D. M. Sabatini, The Pharmacology of mTOR Inhibition. Sci. Signal. 2, pe24 (2009). The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882